GT Biopharma, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 58.01 million compared to USD 28.3 million a year ago. Basic loss per share from continuing operations was USD 2.06 compared to USD 6.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.53 USD | -4.08% | -36.96% | -53.86% |
May. 21 | Top Midday Decliners | MT |
May. 21 | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
1st Jan change | Capi. | |
---|---|---|
-53.86% | 7.61M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.21% | 238B | |
+7.00% | 204B | |
-6.54% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021